Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues / 임상당뇨병
Journal of Korean Diabetes
; : 125-127, 2013.
Article
en Ko
| WPRIM
| ID: wpr-726955
Biblioteca responsable:
WPRO
ABSTRACT
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Péptidos
/
Ponzoñas
/
Glucagón
/
Diabetes Mellitus Tipo 2
/
Péptido 1 Similar al Glucagón
/
Incretinas
/
Liraglutida
/
Hiperglucemia
Límite:
Humans
Idioma:
Ko
Revista:
Journal of Korean Diabetes
Año:
2013
Tipo del documento:
Article